ArticleJournal of clinical medicine research2026
Uncommon Combination of Low Alanine Aminotransferase and High Fatty Liver Index Associated With High Charlson Comorbidity Index: Insights From the K7Ps-Study-7.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated serum alanine aminotransferase (ALT) often reflects fatty liver, whereas low ALT has been reported as a predictor of frailty and increased mortality. However, the association between ALT and the Charlson Comorbidity Index (CCI), a measure of comorbidity and long-term mortality, is unknown. Therefore, this study aimed to investigate the association, particularly focusing on the fatty liver index (FLI) and physical characteristics, in a community-based cross-sectional study. Methods: We examined liver enzymes, CCI, and cardiometabolic factors in 6,418,215 individuals without hepatic cirrhosis. Participants were classified into normal FLI (< 30, n = 4,418,623, NFG) and high FLI group (≥ 30, n = 1,999,592, HFG). A generalized linear model (GLM) was used to assess the association between ALT and CCI. Results: Overall, all variables including CCI, but except for high-density lipoprotein cholesterol and prevalence of women, were higher in HFG than NFG. Age, CCI, and prevalence of cardiovascular disease and stroke increased with rising ALT levels in NFG, whereas they decreased in HFG (all P < 0.0001, linear regression and Cochran-Armitage trend test). Individuals with lower ALT were older, more often women, and those with lower physical capacity in HFG. Results of GLM demonstrated a U-shaped association between ALT and CCI, with the lowest point at ALT 20-29 U/L, after adjusting for covariates in NFG. By contrast, in HFG, lowest ALT of < 10 U/L (n = 17,261, 0.9%) was most associated with CCI than any other categories of ALT, with the lowest point at ALT of 30-49 U/L. Such trends were not observed in aspartate aminotransferase and γ-glutamyl transferase. Conclusions: The uncommon combination of low ALT and fatty liver may be associated with high CCI, and older and more often women with the aspects of frailty, which was disclosed by the consideration of fatty liver, suggesting a phenomenon related to obesity paradox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.